Compositions and methods for the treatment of Parkinson's disease

Patent metadata

Field	Value
Publication number	US-10829454-B2
Application number	US-201615755729-A
Country	US
Kind code	B2
Filing date	Sep 2, 2016
Priority date	Sep 2, 2015
Publication date	Nov 10, 2020
Grant date	Nov 10, 2020

Abstract

The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III, and methods for treating or preventing Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of Parkinson's disease such as Parkinson's disease, scleroderma, restless leg syndrome, hypertension and gestational hypertension.

First claim

What is claimed is:

1. A compound of formula I:

or a pharmaceutically acceptable salt, hydrate, polymorph, solvate, enantiomer, or stereoisomer thereof; wherein R 1 and R 3 each independently represents

wherein, alternatively R 3 can also represent null;
and wherein R 2 and R 4 independently represents OCH 3 , OCD 3 ,

2. A compound of formula II:

or a pharmaceutically acceptable salt, hydrate, polymorph, solvate, enantiomer, or stereoisomer thereof; wherein R 1 and R 3 each independently represents

wherein, alternatively R 3 can also represent null;
and wherein R 2 and R 4 independently represents OCH 3 , OCD 3 ,

3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3 , wherein said pharmaceutical composition is formulated to treat an underlying etiology with an effective amount of the pharmaceutical composition for administering to a patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, depot, spray, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration.

5. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5 , wherein said pharmaceutical composition is formulated to treat an underlying etiology with an effective amount of the pharmaceutical composition for administering to a patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, depot, spray, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration.

7. A method of treating Parkinson's disease, scleroderma, restless leg syndrome, hypertension or gestational hypertension in a patient in need thereof, comprising administering an effective amount of the pharmaceutical composition of claim 4 .

8. A method of treating Parkinson's disease, scleroderma, restless leg syndrome, hypertension or gestational hypertension in a patient in need thereof, comprising administering an effective amount of the pharmaceutical composition of claim 6 .

Assignees

• Cellix Bio Private Ltd

Inventors

• Kandula Mahesh

Classifications

• C07C233/49

  having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton · CPC title

• C07D221/18 Primary

  Ring systems of four or more rings · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• C07C243/30

  to carbon atoms of an unsaturated carbon skeleton · CPC title